Exploratory 4-year Analysis Continues to Support Adding 3 Years of Ribociclib to Adjuvant NSAI for HR-positive, HER2-negative EBC at Risk of Recurrence By Ogkologos - October 8, 2025 95 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the NATALEE study Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR Groundbreaking Trial Results Expand Treatment Options for Some People with Bladder... November 30, 2023 Single Mom Has To Beg For Rides To Doctor For Son... March 14, 2019 Coronavírus e COVID-19: o que as pessoas com câncer precisam saber June 22, 2020 EMA Recommends Granting a Marketing Authorisation for Piflufolastat (18F) June 1, 2023 Load more HOT NEWS Prising open the trap: Getting to grips with targeted cancer drug... Substantial and Durable Overall and Intracranial Activity of Trastuzumab Deruxtecan in... FDA Approves Pembrolizumab and Berahyaluronidase alfa-pmph for Subcutaneous Injection Quality of Life Is Maintained with First-line Nivolumab Plus Ipilimumab in...
